Latest Breaking News On - Escient pharmaceuticalsfor - Page 1 : comparemela.com

Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.

Incyte corporationHoppenot incyteWilliam blairEscient pharmaceuticalsforCantor fitzgerald